U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314242) titled 'A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD' on Dec. 18, 2025.
Brief Summary: A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
COPD (Chronic Obstructive Pulmonary Disease)
Intervention:
DRUG: Hemay005 tablets
Subjects take Hemay005 tablets for 12 weeks.
DRUG: Roflumilast Oral Tablet
Subjects take roflumilas...